Longevity Digest, September 27–October 4: muscles that grow without strength, and a third more life for fast-aging mice
Attia's week on muscle drugs that add mass without strength and on early Alzheimer's prevention anchors a digest in which Rhonda Patrick argues against injecting unverified peptides, Blueprint writes up vitamin D, and Sinclair's lab reports a reprogramming result in fast-aging mice.
This digest covers the public output of Peter Attia, David Sinclair, Bryan Johnson's Blueprint team, and Rhonda Patrick between September 27 and October 4, 2026, Pacific Time. Attia published three times, and two of those items ask what a measurement is worth: drugs that add lean mass to a body without adding strength to it, and an Alzheimer's-prevention strategy that rests on treating the disease earlier than today's drugs do. David Sinclair's lab reported a reprogramming cocktail in fast-aging mice. Rhonda Patrick argued against injecting gray-market peptides and posted new data on bone loss around menopause, while Blueprint wrote a page on vitamin D.
The week in one screen
| Figure | Focus this week | Primary evidence tier | Actionable takeaway |
|---|---|---|---|
| Peter Attia | Muscle drugs that add mass without strength 1; how a drug is built 2; an early Alzheimer's prevention bet 3 | A published, placebo-controlled Phase II trial and a history of failed strength endpoints; a paywalled analysis of Phase III secondary analyses | Resistance training still builds the strength the drugs do not 1 |
| Bryan Johnson / Blueprint | Vitamin D: dose and source 4 | Company content built on one four-year telomere trial and a prevalence estimate | The allowance is 600 IU a day, 800 after 70; Blueprint's founder takes 2,000 4 |
| Rhonda Patrick | Gray-market peptides 5; bone loss at menopause 6; hormone therapy and grip strength 7; exercise and epigenetic aging 8 | An expert position; an observational cohort; a secondary analysis of a randomized trial | Spine bone density fell 7.4% in the three years around the last period 6 |
| David Sinclair | A reprogramming cocktail in fast-aging mice 910 | An unpublished conference pilot in a mouse strain bred to age fast | Treated mice lived longer; the strain carries a mutation that makes it age within months 9 |
Peter Attia: mass without strength, and the long road a drug travels
Peter Attia is a physician, the founder of the Early Medical practice, and the host of The Peter Attia Drive. He published three times in the window.
A drug that adds muscle without adding strength
Attia's October 3 article, written with Michael Rae and Lauren Fritsch, starts from a real worry about the GLP-1 receptor agonists. Rapid weight loss on semaglutide or tirzepatide takes lean tissue along with fat, and the tool that protects lean tissue reaches few people: 30.2% of Americans meet the CDC guideline of two or more resistance-training sessions a week, and 57.8% do none at all 1. Biotech has spent years trying to solve the same problem with a drug.
Apitegromab is the newest of those drugs. It is an antibody that blocks the release of myostatin, a signal muscle cells make to limit their own growth, and in the Phase II EMBRAZE trial it was given on top of tirzepatide to 102 adults with overweight or obesity for 24 weeks 1. Both groups lost about 12 kilograms. The apitegromab group lost less of that as lean mass, 1.6 kg against 3.5 kg, so lean tissue accounted for 14.6% of its weight loss against 30.2% in the placebo group 1.
The strength measurements are where the result stops being clean. On a repeated sit-to-stand test the apitegromab group added 2.4 repetitions and the placebo group added 2.2. Grip strength rose 0.9 kg with apitegromab and fell 0.3 kg without it, a difference the trial did not find statistically significant (p ≈ 0.72) and one that sits inside a spread of about 7 to 8 kg. The median grip of a person the same age is over 38 kg 1. Four and a half pounds of extra lean mass bought no measurable extra force.
Bimagrumab, a second antibody against the same pathway, ran the experiment years earlier and landed in the same place. It went through trials in a rare inflammatory muscle disease, in sarcopenia, in healthy young men and after hip fracture. Muscle volume rose in several of them on magnetic resonance imaging, which is the gold standard for measuring muscle, and function held still: in a one-year trial of 105 people with inclusion body myositis, the higher doses added lean mass while the six-minute walk test and the risk of falls stayed where they were 1. Novartis shelved the antibody. The staff who believed in it founded Versanis Bio, and Eli Lilly bought Versanis in 2023 for $1.92 billion 1. In the company's latest trial, 507 adults with overweight or obesity received bimagrumab, semaglutide, both, or placebo. Every kilogram lost on bimagrumab alone came from fat, and on grip strength and a physical-function questionnaire the groups separated no further than they had before 1.
Growth hormone made the same offer first. A 1990 trial showed men gaining lean mass while losing fat, and a wave of anti-aging practice followed; when larger controlled trials tested growth hormone, the lean-mass effect held and the strength and function measures did not 1. The pattern reaches back further in animals: mice engineered without myostatin grow muscles that are weaker per unit of cross-sectional area than normal mice 1.
Nobody has settled why the two come apart. Lean mass includes organs, skin, bone and water, so part of any gain may not be muscle, though MRI in the bimagrumab trials showed real muscle 1. The hypotheses on the table include fibers that grow faster than the nerve wiring and blood supply that make them usable, and a role for myostatin in development that an adult body cannot reuse 1. One newer drug separates itself on this point. The SARM enobosarm, added to semaglutide in a Phase IIb trial, preserved lean mass and carried a strength signal with it: 19.4% of the enobosarm group lost at least 10% of their stair-climb strength against 42.6% of the placebo group. That number arrives in a company press release, and the drug has a long record of failed development behind it 1.
The article's practical conclusion points where three of the four voices kept pointing this week. Resistance training strengthens tendon and bone as well as muscle, and strength tracks the risk of death more closely than lean mass or muscle volume does 1.
How a drug gets built, and what it costs
Attia's guest on September 28 was Lloyd Klickstein, a physician-scientist who spent two decades at Novartis as global head of translational medicine for its New Indication Discovery Unit, co-led the mTOR and immunosenescence trials with Joan Mannick, co-founded the company that developed bimagrumab, and now leads Koslapp Therapeutics 2. The episode walks through how a medicine is made: how a team picks an unmet need, which drug modalities it can choose from, what patents and capital do to the choice, what a filing for an investigational new drug and GMP manufacturing require, and why the process costs so much and takes so long 2.
Klickstein's account of the problem he set out to solve is the part that ties to the article. Frail older adults entering a nursing home had a three-year mortality rate approaching 90%, a prognosis worse than most cancers, and he wanted first to treat that frailty and then to prevent it 2. The episode also turns to selective mTORC1 inhibition and the difficulty of testing a drug meant to slow aging, and to Klickstein's current work on a pharmacological approach to cancer prevention 2. The detailed show notes, including the sections on GMP manufacturing and gray-market peptides, sit behind the membership paywall; the free page carries the topic list and the opening stretches of the conversation 2.
The end of Alzheimer's?
Attia's third item is a premium article from September 30, by Michael Rae, Taylor Yeater and Attia 3. Its subject is a change of strategy against Alzheimer's dementia. Donanemab and lecanemab, the two antibodies approved to clear aggregated beta-amyloid from the brain, slow cognitive decline, and the size of the effect has disappointed people who expected more from the first therapies that do more than treat symptoms 3.
The article's argument is about timing. By the time mild cognitive impairment or early dementia appears, the brain carries tau aggregates that have spread beyond the medial temporal lobe and support cells that have been driven into a damaging state, and clearing beta-amyloid cannot undo that 3. Companies are now betting that clearing amyloid before that spread begins will delay or prevent the dementia, and trials built on that bet are running. The article's thresholds and trial-by-trial numbers sit behind the paywall; the free page carries the framing 3.
Blueprint: vitamin D, and a store link at the end
Blueprint, Bryan Johnson's protocol company, published once in the window. "Is Vitamin D Good for Longevity?" carries Vanessa Gibbs's byline and is dated September 30 4.
The page is a primer. Vitamin D regulates more than 200 genes; the body converts D2 and D3 into 25-hydroxyvitamin D in the liver and then into the active 1,25-dihydroxyvitamin D in the kidneys, which acts on cell growth, bone formation, immune function, insulin production and blood pressure 4. The recommended dietary allowance is 600 IU a day for adult men and women and 800 IU after 70; Johnson takes 2,000 IU 4. For aging, the page leans on a four-year trial of 2,000 IU of D3 that measured how quickly telomeres shorten 411, and on an estimate that about 77% of people fall short of adequate levels 12. D3 raises 25-hydroxyvitamin D more than D2 does 4.
On sourcing, the page makes a case that runs against the usual advice. Sunlight has to be direct to make vitamin D, darker skin and older age reduce how much the skin produces, and because sun exposure ages skin and raises skin-cancer risk the page treats a supplement as the safer route 4. Blueprint sells supplements, and the page closes on its own capsules, which carry 2,000 IU of D3 alongside 22 other ingredients, under a Food and Drug Administration disclaimer 4.
Rhonda Patrick: what to inject, and what menopause costs
Rhonda Patrick is a biomedical scientist and the host of FoundMyFitness. She published one Aliquot episode, one Science Digest issue and four substantive posts on X in the window.
The case against injecting research peptides
Patrick's September 30 post is a position rather than a study report: she would not inject gray-market "research peptides" 5. Her argument is about what is in the vial. Peptides can act as signaling molecules, and the open question is whether a given vial holds the peptide it claims at the dose it claims, free of microbial contamination, endotoxins, heavy metals and peptide-related impurities 5. She notes that the FDA does not verify the safety, effectiveness or quality of compounded drugs before they reach the market, which leaves the safeguards different rather than absent 5. Her stated threshold for changing her mind is narrow: a specific peptide with credible human evidence, and a source whose testing is transparent and independent 5. The post has drawn more than 100,000 views, and the replies divide over whether sending a vial to a lab settles the question.
The same material runs through Attia's episode. Klickstein's conversation covers gray-market peptides next to the requirements for GMP manufacturing, so the manufacturing argument and the sourcing argument arrive on the same product 2.
Bone loss concentrates around the last period
On September 30 Patrick posted a finding about when bone density leaves a woman's skeleton. In a study of 862 women, spine bone mineral density fell 10.6% over ten years, and 7.4% of that loss happened in a three-year window she calls the transmenopause, running from one year before the final menstrual period to two years after it 6. Femoral bone density fell 9.1% across the decade, with 5.8% lost in the same window, so most of the decade's decline lands in those three years 6. Her recommendation follows from the timing: resistance training and high-impact training around the menopause transition, to slow or prevent the loss 6.
Hormone therapy and grip strength
On September 29 Patrick posted an observational result on menopausal hormone therapy and strength 7. Women with a history of hormone therapy had 2.5% greater grip strength at ages 60 to 64 than women who never used it, and the gap widened to 14.3% among women 80 and older 7. Activity level mattered less than the treatment history. Among women 65 and older, those with a history of hormone therapy and a moderate amount of moderate-intensity activity had 16% greater grip strength, and even the most sedentary women with that history had 14% more than their counterparts who had never used it 7. The underlying paper, "Sex hormones and menopause hormone therapy predict muscle strength across the lifespan" in the Journal of Applied Physiology, reports an association: the women who used hormone therapy may differ from those who did not in ways the analysis cannot separate. Patrick states her own caveat, that regular activity stays central for strength whatever else a woman takes 7.
Exercise moved an epigenetic clock
On October 1 Patrick reported a secondary analysis of a randomized trial in breast cancer survivors 8. The trial assigned 253 survivors who had finished active treatment, had low activity levels and reported cognitive trouble to either a remotely delivered exercise program or a health-and-wellness program that gave them a coach but no exercise coaching 13. The exercise group added about 35 minutes of moderate-to-vigorous activity a week, roughly six minutes a day, on top of what it already did 13.
The cognitive paper found no difference between the groups on its two primary outcomes, processing speed and self-reported cognition, though the exercise group improved more on attention at six and twelve months and on memory at six months only 1314. The companion analysis took blood from a random subset of 124 participants and ran it through two DNA-methylation clocks. Over the twelve months, the health-and-wellness group accumulated nearly ten months of epigenetic aging while the exercise group accumulated about one 1315. Both groups started with epigenetic ages about 8.7 years ahead of their chronological ages 13. Faster epigenetic aging went with worse attention and worse self-reported cognition across both groups, and some of the methylation changes pointed at BDNF signaling, a plausible route to the brain effects 8. The investigators call for larger studies, and the clock result comes from a subgroup while the trial's main cognitive endpoints did not separate.
Two more from FoundMyFitness
Aliquot #152, posted September 28, is a conversation with Kelly Starrett about the sedentary workday: how to break up long stretches of sitting, why a standing desk on its own does not do the work, timing movement around meals, floor sitting for mobility, and a "never do nothing" rule for people who drop a program the moment they miss a session 16. The episode is members-only; the public page carries a 90-second preview and the chapter list 16.
The Science Digest issue dated October 2 collects three studies 17. In a 12-week trial of 73 adults aged 45 to 65, creatine monohydrate at 5 grams twice daily added lean mass both with and without a supervised exercise-and-diet program, and improved leg-press and bench-press strength; creatine also raises muscle water, so part of the lean-mass change may be hydration rather than tissue 1718. An analysis of 4,984 US men found that body fat and waist circumference explained about 18 to 20% of the variation in testosterone levels against 2.5% for age alone, and that a tape measure did about as well as a scan of visceral fat 19. And a 12-week trial of rentosertib, an AI-designed drug for lung scarring, lowered blood-protein estimates of biological age by 2.7 to 3.5 years more than placebo at the 60 mg daily dose by week four; the study cannot tell whether the drug affected aging itself or whether the change came from treating the lung disease 20.
David Sinclair: a reprogramming cocktail in fast-aging mice
David Sinclair is a professor of genetics at Harvard Medical School, the author of Lifespan, and a co-founder of Life Biosciences. His week centered on one result and one aside.
SL-100, second version, in mice that age fast
On October 1 Sinclair posted that Christopher Petty had presented the second version of the lab's reprogramming technology at the Aging Research and Drug Discovery meeting 9. In a pilot study in LAKI mice, a strain bred to age rapidly, Sinclair writes that the treatment gave strong protection against frailty and extended maximum lifespan by more than 33%, and that some treated mice are still alive 9. A scientist who watched the talk described the same session as a first look at SL-100 in mice, where treated animals kept their weight and did not become frailer while untreated animals did, and labelled it early, unpublished data 21.
SL-100 is the name the lab gave its chemical reprogramming cocktail. An October 2 report in Endpoints News describes it as restoring youthful gene expression in brain organoids and extending healthy lifespan in both normal and progeria mice, and says the lab is developing it as a pill 10. Sinclair linked that report the next day with the two words "SL-100 update" 22.
The LAKI strain carries a mutation that makes the mice age and die within months, so a lifespan change in it tests one accelerated-aging model. The numbers come from a pilot presented at a conference, and they have not been through peer review or replication. The lab has reported partial reprogramming in animals for several years, and a related gene-therapy approach it developed is in an early human trial for eye disease; this week's item is the chemical version at an earlier stage 10.
One line on bread
Sinclair's other post on October 2 was a one-line reply to a claim that whole grains are metabolically equivalent to industrial white bread, a claim made with a 2017 paper in Cell Metabolism: "Lower bread in general - whatever the type" 2324. The reply takes bread as a category and carries no new data of its own.
Cross-expert check
Two of the four voices made the same argument about peptides this week from opposite ends of the pipeline. Attia's episode placed gray-market peptides beside the requirements for GMP manufacturing and an investigational new drug filing, which frames an unverified vial as a manufacturing problem 2. Patrick described the same products from the buyer's side: a vial whose contents are unverified, a compounding market the FDA does not check before sale, and her own threshold of human evidence plus independent testing 5. Both treat the obstacle as verification rather than pharmacology.
Muscle ran through three of the four sections. Attia's article keeps resistance training as the intervention that builds strength and notes that strength tracks mortality more closely than lean mass does 1. Patrick's bone and hormone posts both end at resistance and high-impact training for women crossing menopause 67. Sinclair's mouse result is about frailty, which is the same tissue measured at the other end of life 9.
The evidence behind the week's items differs by kind, and that difference decides what a reader can carry away. The myostatin article rests on a published, placebo-controlled Phase II trial, on MRI-verified muscle in earlier trials, and on a long record of strength endpoints that failed to move 1. Patrick's menopause numbers are observational, from a cohort and from a secondary analysis of a trial whose primary outcomes did not separate 6713. The SL-100 result is an unpublished pilot in a mouse strain bred to age fast 9. The vitamin D page is company content standing on one four-year trial and a prevalence estimate 4. A reader who sorts the week by what to act on starts with the published human trial and ends with the conference slides.
What to carry forward
- Put a strength test beside any lean-mass number. The apitegromab and bimagrumab trials moved body composition and left grip and walking tests where they were 1.
- Keep resistance training as the muscle intervention. It builds tendon and bone as well as muscle, and strength tracks the risk of death more closely than lean mass does 1.
- Wait for human evidence and independent testing before injecting a research peptide. The FDA does not check compounded products before they reach the market 5.
- Treat bone as the priority in the years around the last period. Most of a decade's spine and femur loss lands in that three-year window, and resistance and high-impact training are the levers 6.
- Read the hormone-therapy strength finding as observational. The women who used it may differ from those who did not, and activity still matters on its own 7.
- Keep SL-100 filed as a mouse pilot. The result comes from a strain bred to age within months, presented at a conference and not yet reviewed 910.
- Take vitamin D at the recommended allowance. It is 600 IU a day, 800 after 70, and the telomere trial behind the higher 2,000 IU dose ran four years 411.
References
- 1
- 2#409 ‒ Inside modern drug development
peterattiamd.com
- 3The end of Alzheimer's?
peterattiamd.com
- 4Is Vitamin D Good for Longevity?
blueprint.bryanjohnson.co
- 5
- 6
- 7
- 8
- 9
- 10
- 11Vitamin D3 supplementation and telomere length: a 4-year randomized trial
pubmed.ncbi.nlm.nih.gov
- 12Prevalence of vitamin D deficiency
frontiersin.org
- 13
- 14
- 15
- 16Aliquot #152: How to Counteract a Sedentary Workday
foundmyfitness.com
- 17FoundMyFitness Science Digest
foundmyfitness.com
- 18
- 19
- 20
- 21
- 22
- 23
- 24
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.